Cargando…
Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial
BACKGROUND: High-dose donepezil is currently prescribed for patients with Alzheimer’s disease (AD) who showed poor or waning response to a lower dose at the risk of increasing cholinergic side effects. However, the adverse events (AEs) depending on the method of dose escalation have not been clarifi...
Autores principales: | Hong, Yun Jeong, Han, Hyun Jeong, Youn, Young Chul, Park, Kyung Won, Yang, Dong Won, Kim, SangYun, Kim, Hwa Jung, Kim, Ji Eun, Lee, Jae-Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492390/ https://www.ncbi.nlm.nih.gov/pubmed/31039806 http://dx.doi.org/10.1186/s13195-019-0492-1 |
Ejemplares similares
-
Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region
por: Sabbagh, Marwan, et al.
Publicado: (2016) -
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
por: Farlow, Martin, et al.
Publicado: (2011) -
Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
por: Ferris, Steven H, et al.
Publicado: (2011) -
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
por: Tariot, Pierre, et al.
Publicado: (2012) -
Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)